Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.37 |
| ▸ | TPO | P07202 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13287109 | 0.81 | LIPG (0.48) | LIPGCA2CYP2D6TSHRHIF1A | |
| SCHEMBL17539677 | 0.79 | LIPG (0.52) | LIPGCA2ALDH1A1CYP2D6TSHR | |
| SCHEMBL26010250 | 0.78 | PKM (0.50) | LIPGALDH1A1CYP2D6CYP1A2TSHR | |
| SCHEMBL26009770 | 0.78 | LIPG (0.50) | LIPGCA2ALDH1A1CYP2D6TSHR | |
| SCHEMBL18756245 | 0.78 | TSHR (0.67) | CA2CYP2D6TSHRHIF1AMPO | |
| SCHEMBL15981402 | 0.78 | LIPG (0.46) | LIPGALDH1A1KMT2A | |
| SCHEMBL15745843 | 0.78 | CA12 (0.58) | LIPGCA2TSHRMPOCA12 | |
| SCHEMBL15745844 | 0.78 | CA12 (0.58) | LIPGCA2CYP2D6TSHRCA12 | |
| SCHEMBL26486284 | 0.76 | MPO (0.40) | CA2ALDH1A1CYP2D6CYP1A2TSHR | |
| SCHEMBL6348017 | 0.76 | PKM (0.58) | LIPGALDH1A1CYP2D6TSHRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154303-A2 | DYNAMIC-COVALENT HYDROGELS WITH GLUCOSE-SPECIFIC AND GLUCOSE-RESPONSIVE DIBORONATE CROSSLINKING | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2023-08-17 | — | — | WO | disclosed |
| US-6919382-B2 | Preparation and uses of conjugated solid supports for boronic acids | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2005-07-19 | — | — | US | disclosed |
| US-20030044840-A1 | Preparation and uses of conjugated solid supports for boronic acids | GOVERNORS OF THE UNIVERSITY OF ALBERTA, THE (CA) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030044840-A1 | Preparation and uses of conjugated solid supports for boronic acids | SLC43A1, SBDS, SLC7A5 | LIPG 4136/4885CA2 2906/4885ALDH1A1 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.